CDMO icon

Avid Bioservices

12.38 USD
Updated Jan 10, 12:16 PM EST
1 day
0.00%
5 days
0.41%
1 month
0.57%
3 months
21.73%
6 months
67.52%
Year to date
0.49%
1 year
91.34%
5 years
82.06%
10 years
17.12%
 

About: Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Employees: 371

0
Funds holding %
of 6,810 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

65% more capital invested

Capital invested by funds: $469M [Q2] → $773M (+$304M) [Q3]

20% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 49

3.3% more ownership

Funds ownership: 103.49% [Q2] → 106.79% (+3.3%) [Q3]

4% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 24

0% more funds holding

Funds holding: 171 [Q2] → 171 (+0) [Q3]

10% less call options, than puts

Call options by funds: $1.96M | Put options by funds: $2.18M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$12.50
1%
upside
Avg. target
$12.50
1%
upside
High target
$12.50
1%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
RBC Capital
Sean Dodge
53% 1-year accuracy
23 / 43 met price target
1%upside
$12.50
Sector Perform
Downgraded
7 Nov 2024

Financial journalist opinion

Based on 41 articles about CDMO published over the past 30 days

Neutral
Accesswire
1 day ago
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
Neutral
GlobeNewsWire
1 day ago
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand
TUSTIN, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today posted an investor presentation in connection with its pending transaction with GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”) on its investor relations website.
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand
Neutral
Accesswire
1 day ago
Avid Bioservices Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Avid Bioservices Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avid Bioservices, Inc. (CDMO) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avid Bioservices, Inc. (CDMO) And Encourages Shareholders to Reach Out
Neutral
Accesswire
2 days ago
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
Neutral
Business Wire
3 days ago
AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avid Bioservices, Inc. (NasdaqCM: CDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners. Under the terms of the proposed transaction, shareholders of Avid will receive $12.50 in cash for each share of Avid that they own. KSF is seeking to determine whether this consideration and the.
AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO
Neutral
Accesswire
3 days ago
Avid Bioservices Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Avid Bioservices Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
5 days ago
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
Neutral
Accesswire
5 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avid Bioservices, Inc. (CDMO) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avid Bioservices, Inc. (CDMO) and Encourages Shareholders to Learn More About the Investigation
Neutral
Accesswire
6 days ago
Avid Bioservices Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Avid Bioservices Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
Charts implemented using Lightweight Charts™